Full-Time
Clinical Manager
Posted on 6/27/2026
Edwards Lifesciences
10,001+ employees
Develops transcatheter heart valves and devices
No salary listed
Bordeaux, France + 2 more
More locations: France | Remote in France
Remote
Remote in Europe with potential on-site visits to France.
 Biology & Biotech (1) |
|---|
Get referred to Edwards Lifesciences
See people who can refer or advise you
- Bachelor's Degree in related field
- 8 years years experience of previous related medical device and/or clinical experience required
- or in Technical degree in Nursing, 7 years years experience of related medical device and/or clinical experience Required
- Clinical certification in one or more product indications required
- Fluent in both French and professional English
- Educate and train physicians, hospital personnel and hospital staff on all aspects of technical matters related to investigational products and procedures including imaging through conducting and/or coordinating one-on-one ad hoc training sessions and in-service structured education programs on two or more therapies or one highly specialized therapy, while translating training needs, providing consultation on complex situations and proposing dynamic solutions
- Act as a expert in providing education on all aspects on two or more therapies or one highly specialized therapy of assigned device(s), device handling, implantation and troubleshooting techniques related to equipment, tools and products required for device implants including full certification for independent case support while influencing decisions and facilitating new relationships to prepare new sites while influencing decisions and monitoring compliance in new sites
- Lead continuously improvement of training curriculum, training materials and training tools, based on clinical trial experience, EW guidelines and SOP
- Provide coaching, mentoring, and knowledge transfer to team member on launch and complex activities
- Responsible for certification of the centers, physicians and other related staff, as well as EW personnel and as outlined within EW SOP
- Identify potential adoption strategies
- Lead clinical support activities, changes in the market and assigned accounts, as well as, competitive activity with cross-functional teams (e.g., sales)
- Incidental
- Training experience in clinical / technical environment preferred
- Clinical certification in one or more product indications may be listed as required in some postings
- Proven expertise in MS Office Suite and ability to operate general office machinery
- Strong written and verbal communication skills, presentation, and interpersonal relationship skills including facilitating, influencing, negotiating and relationship management skills
- Ability be adaptable and travel to new sites across the region (e.g., Europe); must have a flexible mindset
- Excellent problem-solving and critical thinking skills
- Full knowledge and understanding of cardiovascular science
- Full understanding of cardiovascular anatomy, pathology and physiology including the applications and “language” of the market and Edwards Lifesciences
- Full understanding of medical device regulatory requirements and documents, device accountability and adverse events reporting
- Full imaging analysis software skills (e.g. 3Mensio, TomTec, Vitrea, Circle VI, etc.)
- Ability to manage confidential information with discretion
- Adhere to all company rules and requirements (e.g., pandemic protocols, Environmental Health & Safety rules) and take adequate control measures in preventing injuries to themselves and others as well as to the protection of environment and prevention of pollution under their span of influence/control
Edwards Lifesciences focuses on cardiovascular medical technologies, especially transcatheter heart valves. Its products enable repairing or replacing diseased heart valves through minimally invasive procedures rather than open-heart surgery. The company builds on a long history that began with the Starr-Edwards valve and now centers on valve therapies and related diagnostics to treat heart disease. It differentiates itself by specializing in valve technologies and transcatheter approaches, backed by a track record of clinical leadership and global reach. The goal is to improve patient outcomes by providing safer, less invasive valve treatment options for people around the world.
Company Size
10,001+
Company Stage
IPO
Headquarters
Irvine, California
Founded
1958
Get referred to Edwards Lifesciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Raised 2026 sales guidance to $6.5 billion-$6.9 billion.
- TAVR sales grew 14.4% in Q1 2026 to $1.2 billion.
- Autus expands coverage beyond TAVR into mitral and tricuspid therapies.
What critics are saying
- TAVR remains concentrated, so any growth slowdown hits the core franchise.
- International TAVR volume pressure and tariffs can erode near-term revenue.
- Next-generation mitral and tricuspid programs face clinical, regulatory, and execution risk.
What makes Edwards Lifesciences unique
- Edwards leads structural heart care with transcatheter and surgical valve technologies.
- Its portfolio spans aortic, mitral, tricuspid, and heart failure therapies.
- The company pairs breakthrough devices with clinician partnerships and evidence generation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 9%1 year growth
↑ 9%2 year growth
↑ 9%Vdyne granted IDE to address 'forgotten' valve. Vdyne secures IDE approval to launch a pivotal trial for its TTVR system, positioning itself as a key competitor to Edwards Lifesciences in the growing tricuspid valve replacement market. Omar Ford, Editor-in-Chief, MD+DI, Informa Markets - Engineering April 5, 2026 At a glance. * The tricuspid valve market sees growing competition among top players. * The TTVR system targets patients with severe tricuspid regurgitation. * Edwards' Evoque shows strong data at ACC 75th Annual Expo. Vdyne has been granted an IDE to begin a pivotal trial of its transcatheter tricuspid valve replacement system (TTVR). The device will treat patients suffering from severe tricuspid regurgitation. There is a significant market opportunity for the tricuspid valve, often dubbed the "forgotten valve". "This is a defining milestone for Vdyne and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation," said Mike Buck, Chief Executive Officer. "Our focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care." Vdyne's TTVR system is designed as a patient-tailored, minimally invasive solution to address the complexities of tricuspid valve anatomy and disease. Since its first-in-human use in November 2023, Vdyne said its TTVR system has been used through clinical studies and compassionate use, providing important insights into procedural performance and clinical outcomes. Vdyne's leading competitors in the TTVR market. Vdyne's IDE comes hot on the heels of Edwards Lifesciences presenting strong data at the American College of Cardiology 75th Annual Scientific Session & Expo. During a late-breaking research session, the Irvine, CA-based company revealed two-year data that show its Evoque TTVR system demonstrated significant and sustained patient benefits. Edwards is first to the market with a TTVR system and secured CE mark for Evoque in October of 2023. It won FDA approval for the device in February of 2024. Edwards, which is on the Top 100 Medical Device Companies list, inherited Envoque when it acquired CardiAQ in 2015 for $400 million. There are other companies that are developing TTVR systems. Medtronic, another firm on the Top 100 Medical Device Companies list, scored a breakthrough designation for the Intrepid TTVR system. Medtronic gained access to Intrepid when it acquired Twelve Inc. for about $458 million in 2015. Editor-in-Chief, MD+DI, Informa Markets - Engineering Omar Ford is a seasoned journalist specializing in medical technology, healthcare innovation, and the medical device and diagnostics industry. As the editor-in-chief of Medical Device + Diagnostics Industry (MD+DI), he has earned a reputation as a leading authority in the field, offering in-depth insights into the latest trends, regulatory changes, and technological advancements shaping the future of healthcare. Omar has been a featured speaker at MD&M and MEDevice events. Omar has written for several publications prior to MD+DI. He is a former contributor at Bioworld Medtech, an online publication owned by Clarivate. He was a general assignment reporter for the Beaufort Gazette and an education and county reporter for the Griffin Daily News. He is the 2001 winner of the Judson Chapman Award from the South Carolina Press Association and the 2003 McClatchy President's Award recipient. Omar has a bachelor's degree in print journalism from the University of South Carolina. Throughout his tenure at MD+DI, Omar has covered a wide array of topics, including medical technology innovations, regulatory affairs, market dynamics, and the growing impact of artificial intelligence in healthcare. Omar is the host of the Let's Talk Medtech podcast.
Every Heartbeat Matters | EMERGENCY USA attends Partner Summit. * April 2, 2026 * Events Last week, an EMERGENCY delegation had the opportunity to attend the Every Heartbeat Matters Partner Summit - hosted by Edwards Lifesciences and the Edwards Lifesciences Foundation - alongside other global partners, clinicians, and advocates who share its belief that access to high-quality cardiac care should never depend on where a person is born. Throughout the Summit, likeminded organizations working across surgery, advocacy, training, and systems strengthening reflected on the incredible strides taken so far, shared current progress and challenges, and highlighted the urgent work ahead. The EMERGENCY team also had the opportunity to take part in a Pro Bono Workshop, collaborating directly with Edwards' employees to identify challenges and build roadmaps for solution implementation. Between 2020 and 2025, partners of Edwards' Every Heartbeat Matters initiative impacted over 3.5 million patients who would otherwise have faced barriers to care. Their 2030 vision aims to reach two million more - and EMERGENCY USA is eager to help achieve that goal. Thank you to Edwards Lifesciences for demonstrating leadership and a strong commitment to equitable cardiac care worldwide. Together, Emergency USA is advancing a world where every heartbeat is valued, and every patient has the right to access quality care, free of charge.
Philips has received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, a heart procedure visualisation tool developed with Edwards Lifesciences. The system uses artificial intelligence to track and visualise mitral valve repair devices during minimally invasive procedures. The software combines X-ray fluoroscopy and 3D transesophageal echocardiography outputs to continuously show device location, addressing the challenge of interpreting separate images during transcatheter edge-to-edge repair procedures. The system is designed for use with Edwards' Pascal Ace mitral valve repair system. A recent study of 51 patients found over two-thirds of users rated the software helpful or very helpful, with teams reporting improved discussions about optimal device trajectory in 85% of cases. The clearance updates a product originally launched in 2012.
Philips wins FDA clearance for imaging device developed with Edwards. The system uses AI to optimize the placement of Edwards' mitral valve repair device. Published March 27, 2026 Dive brief: * Philips said Thursday it has received 510(k) clearance for a heart procedure visualization tool it developed with Edwards Lifesciences. * The system, called EchoNavigator R5.0 with DeviceGuide, uses artificial intelligence to enable surgeons to track and visualize mitral valve repair devices during minimally invasive heart procedures. * Philips said the system is intended for use with Edwards' Pascal Ace mitral valve repair system, which competes with Abbott's MitraClip for the transcatheter edge-to-edge repair market. Dive insight: Physicians use X-ray fluoroscopy and 3D transesophageal echocardiography to visualize the heart and device during TEER procedures. However, the technologies create two separate images. The surgical team must interpret where the device is in the body based on the two images, potentially leading to miscommunication and suboptimal device placement. Philips designed its software to combine the outputs of the two imaging modalities to continuously show the location of the device in the body. By visualizing the device in the ultrasound image, the companies aim to enable surgeons to more consistently place the repair system in the optimal location. A paper published this month reported the experiences of physicians who used the system to treat 51 patients. More than two-thirds of users said the software was helpful or very helpful. The 4% of users who said the system was not helpful mainly had device recognition issues in patients with multiple heart implants. Teams said the software improved discussions about optimal trajectory in 85% of cases. The Food and Drug Administration clearance, which updates a product that originally launched in 2012, comes four months after Philips said it was working with Edwards. Philips had already filed for 510(k) clearance when it disclosed the alliance. The collaboration combined Philips' imaging and AI capabilities with Edwards' valvular heart therapy expertise. Bert van Meurs, chief business leader of image-guided therapy at Philips, said at the company's capital markets day last month that DeviceGuide is "a concrete example of how we make emerging complex therapies easier to adopt and scale." Developing such products is only possible by partnering with leading companies in the field, such as Edwards, van Meurs said.
Edwards Lifesciences Corporation has completed its transition into a pure-play structural heart disease company following the divestiture of its Critical Care business to Becton, Dickinson and Company for $4.2 billion in cash. The loss of roughly 20% of its 2023 EBITDA has been offset by its Transcatheter Mitral and Tricuspid Therapies segment, which is growing over 50% year-over-year. The company's core Transcatheter Aortic Valve Replacement franchise generates over $4.5 billion in annual revenue with 12%-plus growth. Trading at approximately $78, Edwards Lifesciences maintains 78% gross margins and $3.8 billion in cash. At 21.3 times EV/NTM EBITDA, the valuation sits below its historical average of 26 times, with expected EBITDA growth of 10–11% CAGR. Sixty-four hedge funds held positions at the end of the third quarter.